Robert Way/iStock Editorial via Getty Images
AstraZeneca (AZN) said its experimental stomach cancer treatment doubled survival time in a late-stage clinical trial, strengthening prospects for a medicine the British drugmaker estimates could generate as much as $5 billion in annual sales.
The drug, sonesitatug vedotin, also known as